**Table S5.** Monotherapy cases in the SGA-LAI group versus oral correspondents.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Antipsychotic (type, formulation) | | Number of patients | Patients stabilized on monotherapy (N, %) | *p-*Value |
| olanzapine | LAI | 5 | 4 (80%) | *p* = 0.18 |
| OAP | 70 | 32 (45.71%) |
| risperidone | LAI | 16 | 8 (50%) | *p* = 0.24 |
| OAP | 31 | 10 (32.25%) |
| aripiprazole | LAI | 9 | 5 (55.55%) | *p* = 0.25 |
| OAP | 24 | 8 (33.33%) |
| paliperidone | LAI | 9 | 4 (44.44%) | *p* = 0.83 |
| OAP | 15 | 6 (40%) |